Actively Recruiting
Comparative Study Between Dexmedetomidine, Magnesium Sulphate, and Lidocaine for Cough Suppression During General Anesthetic Emergence
Led by Al-Azhar University · Updated on 2025-06-11
300
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to compare the effectiveness of dexmedetomidine, magnesium sulfate, and lidocaine in reducing cough during the wake-up phase after general anesthesia. The study is a prospective, randomized, controlled, double-blinded trial focused on measuring both the number and severity of coughs during this critical period. Participants will be randomly assigned to receive one of four treatments 10 minutes before the end of surgery: dexmedetomidine at 0.5 bcg/kg in saline, magnesium sulfate at 30 mg/kg IV in saline, lidocaine at 1.5 mg/kg in saline, or a saline placebo. Each treatment is given in a 10 ml saline solution. This phase 3 study carefully compares these options to assess their impact on cough suppression during anesthetic emergence. During the study, researchers will monitor cough frequency and severity at 0, 10, 20, 30, and 40 minutes after removal of the breathing tube. Additional measurements include intraoperative heart rate, blood pressure, oxygen levels every 15 minutes, and sedation scores after extubation at set intervals. The study involves adults aged 21 to 60 undergoing surgery under general anesthesia, with careful monitoring to evaluate safety and treatment effects until the end of the observation period.
CONDITIONS
Brief Title
Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 21-60 years
- Both genders
- Body mass index < 30 kg/m2
- American Society of Anesthesiology (ASA) physical status I-II
- Mallampati score class I or II
- Patients undergoing surgery under general anesthesia
You will not qualify if you...
- Known allergy to study drugs
- History of psychiatric illness
- Patients with major organ diseases
- Pre-existing neurological deficits
- Body mass index >30 kg/m2
- Active airway infection or history of tracheal and laryngeal surgery
- Lower esophageal sphincter incompetence (and reflux)
- Increased intracranial and intraocular pressure
- Use of cough-inducing medications
- Pregnant, and lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day (during surgery)
Participants receive one of the study drugs or placebo 10 minutes before the end of surgery to evaluate cough suppression during emergence from general anesthesia.
1 visit (in-person, during surgery and immediate recovery)
Duration - 40 minutes after extubation
Participants are monitored for cough severity and sedation scores at multiple time points after extubation.
Multiple assessments at 0, 10, 20, 30, and 40 minutes after extubation
Trial Site Locations
Total: 1 location
1
Faculty of Medicine, Al-Azhar university Assiut, Egypt.
Asyut, Egypt, 2091110
Actively Recruiting
Research Team
M
Medhat H Allam, lecturer.MD
O
Osama H Ahmed, Professor.MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here